Debiopharm is a privately-held Swiss biopharmaceutical company mainly active in development and clinical testing of drug candidates.

[3][4] Initially, the company worked on interferon and, in 1982, it began to focus on triptorelin, after having acquired the rights for its development from Tulane University.

[11] In 2005, Debiopharm acquired the Canadian company H3 Pharma, rebranded Debiovision, to support the development and worldwide registration of its medicines.

[16] In March 2021, Merck KGaA announced the acquisition of Debiopharm's xevinapant program in head and neck cancer for 900 million euros.

[32] In 2020, Debiopharm signed a global license and research agreement with German biotech 3B Pharmaceuticals (3BP) to work on "Debio 0228", a treatment targeting the CAIX (Carbonic anhydrase 9) enzyme to fight the progression of cancer.